Work

Activity of VERU-111, an novel oral α and β tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.302

Authors: Robert H. Getzenberg, James T. Dalton, Duane D. Miller, Mitchell S. Steiner

Institutions: Veru Inc. (United States), University of Michigan, University of Tennessee Health Science Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2790785690

Cites:

Cited by:

Related to: 10